vTv Therapeutics/$VTVT
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About vTv Therapeutics
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
- Ticker
- $VTVT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 26
- Headquarters
- High Point, United States
- Website
- vtvtherapeutics.com
vTv Therapeutics Metrics
BasicAdvanced
$267M
-
-$0.62
-
-
Price and volume
Market cap
$267M
52-week high
$44.00
52-week low
$20.56
Average daily volume
22K
Financial strength
Current ratio
11.191
Quick ratio
10.986
Interest coverage (TTM)
-10,978.00%
Profitability
EBITDA (TTM)
-10.973
Gross margin (TTM)
51.52%
Net profit margin (TTM)
-20.84%
Operating margin (TTM)
-29.80%
Revenue per employee (TTM)
$1,420,000
Management effectiveness
Return on assets (TTM)
-7.70%
Return on equity (TTM)
-10.95%
Valuation
Price to revenue (TTM)
7.241
Price to book
3.83
Price to tangible book (TTM)
3.83
Growth
Revenue change (TTM)
216,600.00%
Earnings per share change (TTM)
-81.68%
3-year revenue growth (CAGR)
1,499.64%
10-year revenue growth (CAGR)
46.27%
3-year earnings per share growth (CAGR)
-60.65%
10-year earnings per share growth (CAGR)
-37.29%
What the Analysts think about vTv Therapeutics
Analyst ratings (Buy, Hold, Sell) for vTv Therapeutics stock.
Analyst projections of the future price of vTv Therapeutics stock.
vTv Therapeutics Financial Performance
Revenues and expenses
vTv Therapeutics Earnings Performance
Company profitability
Upcoming events
No upcoming events
vTv Therapeutics News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.